Harmony Biosciences Holdings (HRMY) Return on Capital Employed (2020 - 2026)
Harmony Biosciences Holdings (HRMY) posted Return on Capital Employed of 17.97% for Q1 2026, down 14.83% sequentially from 21.1% in Q4 2025, and down 491.0% YoY from 4.6% in Q1 2025.
Harmony Biosciences Holdings (HRMY) Return on Capital Employed (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings has reported Return on Capital Employed for 7 years, with the latest figure at 17.97% in Q1 2026.
- Quarterly Return on Capital Employed fell 491.0% year-over-year to 17.97% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.97% (down 491.0% YoY) and the FY2025 annual result came in at 23.6%, down 253.0% from the prior year.
- Return on Capital Employed retreated to 17.97% in Q1 2026 per HRMY's latest filing, from 21.1% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 30.44% in Q4 2023 and troughed at 17.97% in Q1 2026.
- A 5-year average of 24.36% and a median of 24.14% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed jumped 1417 bps in 2022, then plunged 729 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 20.73% in 2022, then jumped by 47 bps to 30.44% in 2023, then decreased by 21 bps to 24.2% in 2024, then fell by 13 bps to 21.1% in 2025, then fell by 15 bps to 17.97% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 17.97%, 21.1%, and 24.14% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn | 21.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.19% |
| Mar 31, 2026 | 17.97% |
| Dec 31, 2025 | 21.10% |
| Sep 30, 2025 | 24.14% |
| Jun 30, 2025 | 24.61% |
| Mar 31, 2025 | 22.89% |
| Dec 31, 2024 | 24.20% |
| Sep 30, 2024 | 23.95% |
| Jun 30, 2024 | 25.22% |
| Mar 31, 2024 | 30.17% |
| Dec 31, 2023 | 30.44% |
| Sep 30, 2023 | 30.38% |
| Jun 30, 2023 | 22.78% |
| Mar 31, 2023 | 21.84% |
| Dec 31, 2022 | 20.73% |
| Sep 30, 2022 | 21.68% |
| Jun 30, 2022 | 26.35% |
| Mar 31, 2022 | 25.64% |
| Dec 31, 2021 | 24.42% |
| Sep 30, 2021 | 20.34% |